- Report
- March 2024
- 197 Pages
Global
From €3212EUR$3,374USD£2,746GBP
€3569EUR$3,749USD£3,051GBP
- Report
- December 2023
- 84 Pages
Global
From €5665EUR$5,950USD£4,842GBP
- Report
- March 2024
- 194 Pages
Global
From €4713EUR$4,950USD£4,028GBP
- Report
- September 2023
- 119 Pages
Global
From €2380EUR$2,500USD£2,035GBP
- Report
- February 2024
- 175 Pages
Global
From €4760EUR$5,000USD£4,069GBP
- Report
- March 2024
- 200 Pages
Global
From €3951EUR$4,150USD£3,377GBP
- Report
- December 2023
- 59 Pages
Global
From €6660EUR$6,995USD£5,693GBP
- Report
- March 2020
- 154 Pages
Global
From €3951EUR$4,150USD£3,377GBP
- Report
- March 2023
- 143 Pages
Global
From €2379EUR$2,499USD£2,034GBP
- Report
- January 2022
- 200 Pages
Global
From €7141EUR$7,500USD£6,104GBP
- Report
- January 2022
- 60 Pages
Global
From €3761EUR$3,950USD£3,215GBP
- Report
- January 2022
- 60 Pages
Global
From €3761EUR$3,950USD£3,215GBP
- Report
- January 2022
- 200 Pages
Global
From €7141EUR$7,500USD£6,104GBP
- Clinical Trials
- October 2021
- 60 Pages
Global
From €1428EUR$1,500USD£1,221GBP
- Report
- April 2022
- 125 Pages
Global
From €4237EUR$4,450USD£3,621GBP
- Report
- July 2019
- 101 Pages
Global
From €4237EUR$4,450USD£3,621GBP
- Report
- August 2021
Global
From €3799EUR$3,990USD£3,247GBP
- Report
- August 2021
Europe
From €3256EUR$3,420USD£2,783GBP
- Report
- February 2021
Global
From €2818EUR$2,960USD£2,409GBP
- Report
- August 2022
United States
From €1847EUR$1,940USD£1,579GBP
Gaucher Disease is a rare genetic disorder caused by the deficiency of an enzyme called glucocerebrosidase. This enzyme is responsible for breaking down a fatty substance called glucocerebroside, which accumulates in the cells of the body, leading to a variety of symptoms. Treatment for Gaucher Disease includes enzyme replacement therapy, substrate reduction therapy, and chaperone therapy.
The Gaucher Disease Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat Gaucher Disease, such as enzyme replacement therapy, substrate reduction therapy, and chaperone therapy. These drugs are used to reduce the symptoms of Gaucher Disease and improve the quality of life of those affected.
Some companies in the Gaucher Disease Drug market include Sanofi, Shire, Pfizer, and Genzyme. Show Less Read more